BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis



Status:Archived
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:October 2008
End Date:September 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.


Phase I study designed to determine the safety and tolerability of a single dose of BIIB023
administered intravenously versus placebo to subjects with RA.



We found this trial at
4
sites
Clinical Trial Facility in Birmingham Alabama
Birmingham, Alabama
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Research Centre
Duncansville, Pennsylvania
2201
mi
from 91732
Duncansville, PA
Click here to add this to my saved trials
Clinical Trial Facility in Oklahoma City Oklahoma
Oklahoma City, Oklahoma
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Research Centre
Palm Desert, California
96
mi
from 91732
Palm Desert, CA
Click here to add this to my saved trials